vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Solo Brands, Inc. (SBDS). Click either name above to swap in a different company.

Solo Brands, Inc. is the larger business by last-quarter revenue ($94.0M vs $62.1M, roughly 1.5× Cytek Biosciences, Inc.). Cytek Biosciences, Inc. runs the higher net margin — -70.9% vs -88.4%, a 17.5% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -34.5%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 5.0%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Conagra Brands, Inc. is an American consumer packaged goods holding company that makes and sells products under various brand names that are available in supermarkets, restaurants, and food service establishments. Based on its 2021 revenue, the company ranked 331st on the 2022 Fortune 500. Headquartered in Chicago, Illinois, Conagra was founded in Nebraska in 1919 and was originally called Nebraska Consolidated Mills.

CTKB vs SBDS — Head-to-Head

Bigger by revenue
SBDS
SBDS
1.5× larger
SBDS
$94.0M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+42.6% gap
CTKB
8.1%
-34.5%
SBDS
Higher net margin
CTKB
CTKB
17.5% more per $
CTKB
-70.9%
-88.4%
SBDS
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
5.0%
SBDS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
SBDS
SBDS
Revenue
$62.1M
$94.0M
Net Profit
$-44.1M
$-83.2M
Gross Margin
52.9%
60.6%
Operating Margin
-9.0%
-81.7%
Net Margin
-70.9%
-88.4%
Revenue YoY
8.1%
-34.5%
Net Profit YoY
-557.1%
-42.9%
EPS (diluted)
$-45.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
SBDS
SBDS
Q4 25
$62.1M
$94.0M
Q3 25
$52.3M
$53.0M
Q2 25
$45.6M
$92.3M
Q1 25
$41.5M
$77.3M
Q4 24
$57.5M
$143.5M
Q3 24
$51.5M
$94.1M
Q2 24
$46.6M
$131.6M
Q1 24
$44.9M
$85.3M
Net Profit
CTKB
CTKB
SBDS
SBDS
Q4 25
$-44.1M
$-83.2M
Q3 25
$-5.5M
$-22.9M
Q2 25
$-5.6M
$-20.8M
Q1 25
$-11.4M
$-18.6M
Q4 24
$9.6M
$-58.2M
Q3 24
$941.0K
$-111.5M
Q2 24
$-10.4M
$-4.0M
Q1 24
$-6.2M
$-6.5M
Gross Margin
CTKB
CTKB
SBDS
SBDS
Q4 25
52.9%
60.6%
Q3 25
52.7%
60.0%
Q2 25
52.3%
61.3%
Q1 25
48.6%
55.2%
Q4 24
58.5%
61.1%
Q3 24
56.3%
41.8%
Q2 24
54.6%
62.8%
Q1 24
51.3%
59.2%
Operating Margin
CTKB
CTKB
SBDS
SBDS
Q4 25
-9.0%
-81.7%
Q3 25
-17.6%
-30.5%
Q2 25
-23.3%
-10.7%
Q1 25
-36.1%
-13.8%
Q4 24
5.2%
-38.5%
Q3 24
-8.2%
-122.5%
Q2 24
-18.3%
1.7%
Q1 24
-23.9%
-7.4%
Net Margin
CTKB
CTKB
SBDS
SBDS
Q4 25
-70.9%
-88.4%
Q3 25
-10.5%
-43.2%
Q2 25
-12.2%
-22.5%
Q1 25
-27.5%
-24.0%
Q4 24
16.8%
-40.6%
Q3 24
1.8%
-118.4%
Q2 24
-22.4%
-3.1%
Q1 24
-13.8%
-7.6%
EPS (diluted)
CTKB
CTKB
SBDS
SBDS
Q4 25
$-45.73
Q3 25
$-9.22
Q2 25
$-8.93
Q1 25
$-0.21
Q4 24
$-27.74
Q3 24
$-47.72
Q2 24
$-2.14
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
SBDS
SBDS
Cash + ST InvestmentsLiquidity on hand
$90.9M
$20.0M
Total DebtLower is stronger
$242.1M
Stockholders' EquityBook value
$341.7M
$46.0M
Total Assets
$461.5M
$360.3M
Debt / EquityLower = less leverage
5.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
SBDS
SBDS
Q4 25
$90.9M
$20.0M
Q3 25
$93.3M
$16.3M
Q2 25
$75.5M
$18.1M
Q1 25
$95.3M
$206.4M
Q4 24
$98.7M
$12.0M
Q3 24
$162.3M
$12.5M
Q2 24
$177.9M
$20.1M
Q1 24
$168.8M
$15.4M
Total Debt
CTKB
CTKB
SBDS
SBDS
Q4 25
$242.1M
Q3 25
$235.2M
Q2 25
$238.4M
Q1 25
$427.9M
Q4 24
$150.7M
Q3 24
$161.1M
Q2 24
$162.2M
Q1 24
$170.2M
Stockholders' Equity
CTKB
CTKB
SBDS
SBDS
Q4 25
$341.7M
$46.0M
Q3 25
$378.6M
$99.1M
Q2 25
$377.6M
$113.2M
Q1 25
$379.6M
$121.7M
Q4 24
$395.7M
$133.7M
Q3 24
$385.5M
$168.0M
Q2 24
$389.1M
$236.7M
Q1 24
$392.6M
$238.5M
Total Assets
CTKB
CTKB
SBDS
SBDS
Q4 25
$461.5M
$360.3M
Q3 25
$494.9M
$431.0M
Q2 25
$493.3M
$459.7M
Q1 25
$482.6M
$692.4M
Q4 24
$499.5M
$495.1M
Q3 24
$491.2M
$553.2M
Q2 24
$483.7M
$642.0M
Q1 24
$492.1M
$648.3M
Debt / Equity
CTKB
CTKB
SBDS
SBDS
Q4 25
5.26×
Q3 25
2.37×
Q2 25
2.11×
Q1 25
3.52×
Q4 24
1.13×
Q3 24
0.96×
Q2 24
0.69×
Q1 24
0.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
SBDS
SBDS
Operating Cash FlowLast quarter
$-771.0K
$6.4M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-2.9%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
SBDS
SBDS
Q4 25
$-771.0K
$6.4M
Q3 25
$-3.9M
$11.2M
Q2 25
$108.0K
$10.9M
Q1 25
$-125.0K
$-75.2M
Q4 24
$2.0M
$13.0M
Q3 24
$13.2M
$378.0K
Q2 24
$6.2M
$15.7M
Q1 24
$4.0M
$-18.5M
Free Cash Flow
CTKB
CTKB
SBDS
SBDS
Q4 25
$-1.8M
Q3 25
$-4.6M
Q2 25
$-1.5M
Q1 25
$-974.0K
$-78.4M
Q4 24
$1.1M
$9.0M
Q3 24
$12.2M
$-5.9M
Q2 24
$5.2M
$12.8M
Q1 24
$3.4M
$-20.9M
FCF Margin
CTKB
CTKB
SBDS
SBDS
Q4 25
-2.9%
Q3 25
-8.7%
Q2 25
-3.2%
Q1 25
-2.3%
-101.5%
Q4 24
1.9%
6.3%
Q3 24
23.7%
-6.3%
Q2 24
11.0%
9.8%
Q1 24
7.6%
-24.5%
Capex Intensity
CTKB
CTKB
SBDS
SBDS
Q4 25
1.6%
Q3 25
1.3%
Q2 25
3.5%
Q1 25
2.0%
4.2%
Q4 24
1.6%
2.8%
Q3 24
2.0%
6.7%
Q2 24
2.3%
2.2%
Q1 24
1.3%
2.8%
Cash Conversion
CTKB
CTKB
SBDS
SBDS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.21×
Q3 24
14.05×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

SBDS
SBDS

Sales Channel Directly To Consumer$65.4M70%
Sales Channel Through Intermediary$28.6M30%

Related Comparisons